BTW
ANIK icon

Boston Trust Walden’s Anika Therapeutics ANIK Stock Holding History

Boston Trust Walden’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-375,070
Closed -$15.3M – 386
2021
Q1 		$15.3M Sell
375,070
-3,097
-0.8% -$117K 0.15% 189
2020
Q4 		$17.1M Buy
378,167
+2,669
+0.7% +$101K 0.18% 162
2020
Q3 		$13.3M Buy
375,498
+17,016
+5% +$615K 0.17% 171
2020
Q2 		$13.5M Buy
358,482
+32,163
+10% +$1.06M 0.18% 170
2020
Q1 		$9.43M Buy
326,319
+106,501
+48% +$4.31M 0.15% 183
2019
Q4 		$11.4M Sell
219,818
-151,778
-41% -$8.82M 0.13% 200
2019
Q3 		$20.4M Buy
371,596
+406
+0.1% +$20.8K 0.26% 117
2019
Q2 		$15.1M Buy
371,190
+107,675
+41% +$3.93M 0.2% 150
2019
Q1 		$7.97M Buy
263,515
+13,978
+6% +$479K 0.11% 205
2018
Q4 		$8.39M Buy
249,537
+33,406
+15% +$1.21M 0.13% 190
2018
Q3 		$9.12M Sell
216,131
-11,942
-5% -$472K 0.13% 196
2018
Q2 		$7.3M Sell
228,073
-5,662
-2% -$233K 0.11% 209
2018
Q1 		$11.6M Sell
233,735
-16,413
-7% -$927K 0.18% 165
2017
Q4 		$13.5M Sell
250,148
-7,130
-3% -$395K 0.2% 148
2017
Q3 		$14.9M Sell
257,278
-4,714
-2% -$246K 0.23% 131
2017
Q2 		$12.9M Sell
261,992
-79,257
-23% -$3.65M 0.21% 141
2017
Q1 		$14.8M Sell
341,249
-43,773
-11% -$2.09M 0.23% 143
2016
Q4 		$18.9M Sell
385,022
-15,622
-4% -$722K 0.3% 130
2016
Q3 		$19.2M Sell
400,644
-85,750
-18% -$4.24M 0.32% 125
2016
Q2 		$26.1M Sell
486,394
-7,386
-1% -$348K 0.45% 79
2016
Q1 		$22.1M Sell
493,780
-5,757
-1% -$234K 0.38% 101
2015
Q4 		$19.1M Sell
499,537
-187,999
-27% -$7.19M 0.35% 111
2015
Q3 		$21.9M Buy
687,536
+5,336
+0.8% +$186K 0.37% 111
2015
Q2 		$22.5M Sell
682,200
-17,362
-2% -$619K 0.34% 130
2015
Q1 		$28.8M Sell
699,562
-14,385
-2% -$582K 0.43% 105
2014
Q4 		$29.1M Buy
713,947
+315,733
+79% +$12.3M 0.43% 106
2014
Q3 		$14.6M Buy
+398,214
New +$17.2M 0.23% 158

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Boston Trust Walden's ANIK Position: Q2 2021 in Review

Boston Trust Walden sold out of Anika Therapeutics (ANIK) in Q2 2021, closing a stake of 375,070 shares — an estimated $15.3M sold.

Boston Trust Walden first reported a position in ANIK in Q3 2014 and held it in 27 quarters. The position peaked at $29.1M in Q4 2014. 139 funds tracked by Wall St. Rank hold ANIK as of Q2 2021.

  • Boston Trust Walden reported no remaining Anika Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Boston Trust Walden sold 375,070 Anika Therapeutics shares in Q2 2021, an estimated $15.3M.
  • Boston Trust Walden first reported a position in Anika Therapeutics in Q3 2014 and held it in 27 quarters.
  • Boston Trust Walden's Anika Therapeutics position peaked at $29.1M in Q4 2014.
  • 139 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2021.

Based on Boston Trust Walden's 13F filing for Q2 2021, filed 22 Jul 2021.